1. Home
  2. Investor Relations
  3. Announcements and Circulars
Announcements and Circulars Financial Reports Prospectus Corporate Governance Contact IR
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026
2026-08-29
Download
VOLUNTARY ANNOUNCEMENT - HX9428 FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION GRANTED FAST TRACK DESIGNATION (FTD) BY THE U.S. FDA
2026-08-17
Download
DATE OF MEETING OF THE BOARD OF DIRECTORS
2026-08-12
Download
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO PROPOSED CHANGE OF EXTERNAL AUDITOR
2026-08-11
Download
VOLUNTARY ANNOUNCEMENT - IND APPLICATION OF HX9428 FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION APPROVED BY THE U.S. FDA TO COMMENCE PHASE II CLINICAL TRIAL; AND INITIATION OF THE SECOND POSITIVE-CONTROLLED PHASE II CLINICAL TRIAL IN CHINA
2026-08-04
Download
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
2026-08-04
Download
About Us
Technology
Products
News
Investor Relations
Careers
Contact Us

Fujian Haixi Pharmaceutical Co., Ltd. Fujian ICP Record No. 12015727 Internet Drug Information Service Qualification Certificate No.: (Min)-Non-operating-2023-0063

Some texts and images on this website are sourced from the Internet for sharing and learning purposes only. If any content infringes your rights and interests, please notify us promptly, and we will handle or remove the relevant materials without delay.